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An Examination of the Effects of Atorvastatin and Parathyroid Hormone
on Osteoblast Activity
Abstract
HMG-CoA reductase inhibitors, also known as statins, are a ubiquitous class of medication used for lowering
cholesterol. In-vitro and animal studies have suggested that statins can activate osteoblast differentiation and
have anabolic effects on bones; however, observational and experimental studies in humans have shown
conflicting results.1-5 The exact mechanism of statins on bone growth is unknown; however, there are several
hypotheses. The “Lipid Hypothesis” (Figure 1) suggests that lipid oxidation leads to activation of PPARγ, and
production of isoprostanes including isoPGF2α and isoPGEα. PPARγ is associated with inhibition of
osteoblast differentiation, while isoprostanes markers are associated with the induction of osteoclast
differentiation and inhibition of osteoblast differentiation. This led to the the hypothesis that statins can
decrease lipid oxidation, which can inhibit the action of PPARγ and isoprostane-mediated bone loss.6 The
“statins hypothesis” (Figure 2) suggests that the anabolic bone activity of statins is due to the induction of
osteoblast differentiation, suppression of osteoblast apoptosis and inhibiting osteoclastogenesis. Statins
inhibits HMG-CoA reductase, which decrease the productions of isoprenoids farnesyl pyrophosphate (FPP)
and Geranylgeranyl pyrophosphate (GGPP). The decrease in FPP and GGPP leads to upregulation of bone
morphogenetic protein-2 (BMP-2) downstream, stimulating bone formation by increasing mesenchymal
condensation. Statins inhibit osteoblast apoptosis by upregulating TGFβ/Smad3 kinases signaling. It also
decreases osteoclastogenesis by upregulating osteoprotegerin (OPG), a decoy receptor that binds to RANKL
to inhibit osteoclast differentiation.6
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Materials 
A pre-osteoblast cell line, mouse MC3T3-E1 subclone 4 (ATCC® CRL-2593TM), was used in this 
study.  Fetal bovine serum (10%), penicillin-streptomycin (1%) and Alpha Minimum Essential 
Medium (α-MEM) were combined to make growth media.  Differentiation media was prepared by 
adding ascorbic acid (50 ug/mL) and β-glycerol phosphate (10mM concentration) to the growth 
media.  Atorvastatin treatment solution was prepared by dissolving atorvastatin in dimethyl 
sulfoxide (DMSO), then further diluted with differentiation media.  Parathyroid hormone was 
dissolved in water and further diluted with differentiation media.   
 
Experiments 
Pre-osteoblast cells were incubated in growth media at 37oC for two days to allow for 
proliferation, and then they were incubated in differentiation media at 37oC to allow for 
differentiation into osteoblast cells.  After two days of incubation, cells were treated with 
atorvastatin (10-6 or 10-7 M), PTH (10-8 M) or both in differentiation media.  Osteoblast activity 
was assessed using three different tests: an MTT proliferation assay to determine cell survival 
after eight days of treatment, Alazarin Red S staining to determine calcium deposition after 16 
days of treatment, and an alkaline phosphatase assay (Abnova Corporation) to determine alkaline 
phosphatase activity after 3 days of treatment.   
 
Statistical Analysis 
Statistical analysis was performed with one way ANOVA and a Bonferroni post-hoc test; p values < 
0.05 were considered statistically significant. 
To investigate whether statins have an effect on osteoblast growth when used alone and whether 
they have an additive effect on anabolic activities when used with parathyroid hormone.  
Author Disclosure Panel: All authors of this presentation have nothing to disclose concerning possible 
financial or personal relationships with commercial entities that may have a direct or indirect interest in the 
subject matter of this presentation. 
RESULTS 
RESULTS (continued) 
BACKGROUND 
HMG-CoA reductase inhibitors, also known as statins, are a ubiquitous class of medication used 
for lowering cholesterol.  In-vitro and animal studies have suggested that statins can activate 
osteoblast differentiation and have anabolic effects on bones; however, observational and 
experimental studies in humans have shown conflicting results.1-5 
 
The exact mechanism of statins on bone growth is unknown; however, there are several 
hypotheses.  The “Lipid Hypothesis” (Figure 1) suggests that lipid oxidation leads to activation of 
PPARγ, and production of isoprostanes including isoPGF2α and isoPGEα. PPARγ is associated with 
inhibition of osteoblast differentiation, while isoprostanes markers are associated with the 
induction of osteoclast differentiation and inhibition of osteoblast differentiation.  This led to the 
the hypothesis that statins can decrease lipid oxidation, which can inhibit the action of PPARγ and 
isoprostane-mediated bone loss.6 
 
The “statins hypothesis” (Figure 2) suggests that the anabolic bone activity of statins is due to the 
induction of osteoblast differentiation, suppression of osteoblast apoptosis and inhibiting 
osteoclastogenesis.  Statins inhibits HMG-CoA reductase, which decrease the productions of 
isoprenoids farnesyl pyrophosphate (FPP) and Geranylgeranyl pyrophosphate (GGPP).  The 
decrease in FPP and GGPP leads to upregulation of bone morphogenetic protein-2 (BMP-2) 
downstream, stimulating bone formation by increasing mesenchymal condensation.  Statins 
inhibit osteoblast apoptosis by upregulating TGFβ/Smad3 kinases signaling.  It also decreases 
osteoclastogenesis by upregulating osteoprotegerin (OPG), a decoy receptor that binds to RANKL 
to inhibit osteoclast differentiation.6 
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OBJECTIVE 
METHODS 
CONCLUSION 
• Atorvastatin alone does not have an anabolic effect on osteoblast activity, as measured 
by cell survival, calcium staining, and alkaline phosphatase activity.   
• Additive effects of atorvastatin on alkaline phosphatase activity may be present when 
treated in combination with pulsatile PTH.   
• Due to the assumed absence of osteoclasts in culture, continuous PTH suppressed 
osteoblast activity.  Further test will be needed to investigate this effect.  
• Further studies are needed to test for additive effects of atorvastatin and pulsatile PTH 
on cell survival and calcium deposition.  
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Figure 1.  The “Lipid Hypothesis” states that statins decrease circulating 
lipids, which can reduce the generation of reactive oxidative species-
induced cytokines that can lead to osteoporotic bone.  This image is 
adapted from Esposito et al.6 
Figure 2.  The “Statins Hypothesis” states that its action on the estrogen 
receptor, HMG-CoA, and the TGFβ receptors can lead to the inhibition of 
osteoclast differentiation, induction of osteoblast differentiation and the 
prevention of osteoblast apoptosis, which leads to an increased bone 
density.  This image is adapted from Esposito et al.6 
Figure 3.  Osteoblast proliferation in 
cells treated with atorvastatin, 
parathyroid hormone or both.  Cell 
proliferation was significantly reduced 
in cells treated with parathyroid 
hormone with and without atorvastatin 
compared to control and atorvastatin 
alone.  PTH treatment was continuous 
in this study.  * denotes p<0.001.  
Parathyroid hormone is abbreviated 
“PTH”.   
Figure 4.  Calcium deposition in cells 
treated with atorvastatin, parathyroid 
hormone or both.  Calcium deposition 
was significantly reduced in cells 
treated with parathyroid hormone with 
and without atorvastatin compared to 
control and atorvastatin alone. PTH 
treatment was continuous in this study.  
* denotes p<0.001.  Parathyroid 
hormone is abbreviated “PTH”.   
Figure 5.  Osteoblast activity in cells treated with atorvastatin, parathyroid hormone or both.  There was an increase in osteoblast 
activity when parathyroid hormone was administered in a pulsatile fashion compared to the continuous treatment.   Atorvastatin 
alone did not increase alkaline phosphatase activity; however, there appears to be an additive effect on alkaline phosphatase 
activity when cells were treated with atorvastatin and parathyroid hormone in combination compared to either agent alone.  More 
replicates are needed to determine statistical significance.  Parathyroid hormone is abbreviated “PTH”. 
